title: Adult T-Cell Leukemia/Lymphoma: Rarely Encountered in the United States.
abstract: Adult T-cell leukemia/lymphoma (ATLL) is aggressive mature T-cell lymphoproliferative disorder with a poor outcome.
  
  
  
  We present 10 patients with acute and lymphomatous subtypes of ATLL treated with distinct induction regimens, including CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine [Oncovin], prednisone or prednisolone), interferon/zidovudine, and VCAP-AMP-VECP (vincristine, cyclophosphamide, doxorubicin, prednisone; doxorubicin, ranimustine, prednisone; vindesine, etoposide, carboplatin, prednisone).
  
  
  
  The overall response rate was 50%, with 10% complete remission (CR). Two patients achieved CR with the second-line regimen. Three patients underwent consolidation with allogeneic stem cell transplantation (ASCT) in the first CR. The median overall survival was 51 months for the entire group and 84 months for the patients who had undergone ASCT versus 34 months for the non-ASCT patients.
authors: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Electronic address: Christa.Roe@moffitt.org.
authors: Christa
authors: C
authors: Roe
authors: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
authors: Rami
authors: R
authors: Komrokji
authors: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
authors: Ling
authors: L
authors: Zhang
authors: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
authors: Samantha
authors: S
authors: Price
authors: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
authors: Lubomir
authors: L
authors: Sokol
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015415:Biomarkers; D001773:Blood Cells / Q000473:pathology; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016130:Immunophenotyping; D053208:Kaplan-Meier Estimate; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000175:diagnosis* / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D012074:Remission Induction; D012189:Retrospective Studies; D012867:Skin / Q000473:pathology; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014481:United States; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D015415:Biomarkers; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
keywords: Adult T-cell lymphoma; Human T-lymphotrophic virus 1; Non-Hodgkin lymphoma; Peripheral T-cell lymphoma; Retrovirus